| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Robert L Van Nostrand is Director at SLS. Robert L Van Nostrand's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $735K at current prices.
Net of sales, the SLS filings show accumulation of 10,000 shares.
Robert L Van Nostrand has 11 Form 4 filings on record from March 2018 to January 2026, all as Director at SELLAS Life Sciences Group (SLS), 2018–2026.
The 15 reported transactions were 9 option or other derivative awards, 5 stock awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $15K and no sales.
The only open-market purchase was 10,000 shares of SLS at an average $1.48 on June 12, 2025, about $15K. Twelve months later SLS was up 375%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 12, 2025 | SLS Sellas Life Sciences Group, Inc. | Director | Buy | 10,000 | $1.48 | $14,800.00 | +96.2% | +13.9% | +374.5% |